How to Manage Estrogen on TRT
Your testosterone goes in, your estrogen goes up, and your doctor hands you a prescription for anastrozole. That is the standard sequence at most TRT clinics, and it skips over every question that actually matters.
To understand why, you need the full map first.
Testosterone does not just circulate in your blood and do its job. Some of it gets intercepted by an enzyme called aromatase, which is a cytochrome P450 enzyme that converts androgens into estrogens, specifically converting testosterone into estradiol. This conversion happens continuously in multiple tissues throughout your body, including your brain, your bone, your liver, and your skin. But in men, roughly 80% of circulating estradiol comes from one place: adipose tissue, which is body fat. The other 20% comes directly from the testes. So when estradiol climbs on TRT, the question is not how to block the enzyme. The question is what is making the enzyme so active in the first place.
That answer lives in the drivers.
The first and most significant driver is body fat. Aromatase gene expression in adipose tissue is controlled by a specific promoter region that responds to glucocorticoids, inflammatory signals like TNF-alpha, and a class of proteins called cytokines. When a man carries more body fat, he has more aromatase-expressing tissue, which means more conversion happening at any given testosterone level. This is not a passive relationship. Research from Chand and colleagues showed that weight gain and inflammation both independently upregulate aromatase expression in male adipose tissue, which means the more inflamed or overfat the tissue, the more aggressively it converts.
The second driver is how you inject, and this one is purely mechanical.
Aromatase is what researchers call substrate-driven. The more testosterone you flood into the system at once, the more raw material you hand to every aromatase molecule in your body, and conversion goes up proportionally. Testosterone cypionate has an elimination half-life of approximately 4.5 days and a mean residence time of about 8.5 days. When you inject a full weekly dose in one shot, testosterone peaks within 24 to 48 hours. Estradiol trails that peak by about one to two days, spiking around day three to four. Then both drop toward a trough by day seven. The peak-to-trough swing is large, and it is during those testosterone peaks that estradiol climbs into the range that causes symptoms: water retention, mood shifts, nipple sensitivity.
Splitting that same weekly dose into two injections reduces peak-to-trough variance by approximately 30%. Splitting it into daily injections reduces the variance further, mimicking the body's natural production pattern of roughly 6 to 7 milligrams of testosterone per day. The total weekly dose has not changed. But the peaks have flattened, and with smaller peaks comes less substrate hitting the enzyme at any one time, which means lower estradiol spikes. Not necessarily lower average estradiol over the week, but the symptomatic highs disappear. That distinction matters because most symptoms attributed to high estrogen are not about average levels. They are about peak levels.
The other drivers compound everything above. Alcohol directly increases aromatase activity. Insulin resistance affects both aromatase expression and something called SHBG, which stands for sex hormone binding globulin, a protein that binds testosterone in the bloodstream and determines how much is free to be converted. Elevated cortisol from chronic stress or poor sleep activates aromatase expression through the same promoter pathway that body fat inflammation uses. And genetics produce real variation in how aggressively individuals express the CYP19A1 gene that codes for aromatase. Two men on the same protocol at the same body fat percentage can end up with meaningfully different estradiol levels for reasons that are entirely encoded in their DNA.
This is the system you are working within. And this is the system most clinics skip before writing the anastrozole prescription.
Here is why that matters mechanically, not just philosophically.
A study published in the New England Journal of Medicine by Finkelstein and colleagues took 400 healthy men aged 20 to 50, suppressed their natural hormone production with goserelin, and then gave them varying doses of testosterone with or without anastrozole to block aromatization. The result: blocking aromatization while testosterone remained present caused a statistically significant decrease in sexual desire (P less than 0.001) and erectile function (P equals 0.022). Subcutaneous fat area increased two to three times in groups with suppressed estrogen. The study isolated estrogen's independent role in those outcomes because testosterone was still present throughout. It was the estrogen that was gone.
A separate double-blind randomized controlled trial by Burnett-Bowie and colleagues followed 69 men over 12 months on 1 milligram of anastrozole daily versus placebo. Spine bone mineral density decreased significantly in the anastrozole group (P equals 0.0014), despite only a modest estrogen reduction from approximately 15 to 12 pg/mL. That is a 20% drop in estradiol producing measurable bone loss in one year.
This is the clinical trap. A man starts TRT on weekly injections, develops high estrogen symptoms from the peaks, gets prescribed anastrozole, and now has low estrogen symptoms: joint pain, erectile dysfunction, depression, bone loss. The clinic adjusts the anastrozole dose. The patient oscillates. He is now on two drugs to manage a problem that a different injection schedule and some lifestyle work would likely have solved without any additional medication.
The first practical step is to get a test that actually tells you where your estradiol is. Standard immunoassay tests used in most labs cross-react with other steroids in men and produce inaccurate readings. The test you want is called LC-MS/MS, which stands for liquid chromatography tandem mass spectrometry, and it is the gold standard for measuring estradiol in men. A typical target range for men on standard TRT doses is 20 to 35 pg/mL, though levels in the 40 to 60 range can be acceptable in men on higher doses who feel well.
Once you know where you actually are, you work the drivers. Injection frequency is the most controllable lever with the clearest mechanism behind it. Body composition is the highest-leverage long-term change. Alcohol, sleep, stress, and insulin sensitivity all feed into aromatase expression through documented pathways, and all of them are modifiable before any drug enters the picture.
Anastrozole is not FDA-approved for use in men. Every prescription in a TRT context is off-label, and the downstream effects on bone, sexual function, cardiovascular health, and mood are real and well-documented. That does not mean there is never a case for it. There are men with genetic variants in CYP19A1 that drive conversion high regardless of protocol, men at healthy body weight with optimal injection frequency who still land at levels that cause symptoms. Those cases exist. But they are the exception, and they come after everything upstream has been addressed.
Most men are prescribed an aromatase inhibitor before anyone asks what is driving the aromatase.
References
- Finkelstein JS, Lee H, Burnett-Bowie SA, et al. 2013. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 36911, 1011-1022. Source
- Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. 2009. Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 9412, 4785-4792. Source
- Pastuszak AW, et al. 2022. Pharmacokinetics of Testosterone Cypionate Delivered via Subcutaneous Autoinjector. Andrology. Source
- Chand AL, et al. (2015). Weight gain and inflammation regulate aromatase expression in male adipose tissue. Journal of Steroid Biochemistry and Molecular Biology.
- Bhasin S, Brito JP, Cunningham GR, et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM, 103(5), 1715-1744.
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.